Compare SBGI & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBGI | CSTL |
|---|---|---|
| Founded | 1986 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 883.7M | 722.8M |
| IPO Year | 2023 | 2019 |
| Metric | SBGI | CSTL |
|---|---|---|
| Price | $14.83 | $34.32 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $17.64 | ★ $48.20 |
| AVG Volume (30 Days) | ★ 728.9K | 377.1K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 6.67% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,169,000,000.00 | $344,229,000.00 |
| Revenue This Year | $11.93 | $12.74 |
| Revenue Next Year | N/A | $11.78 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $11.83 | $17.72 |
| 52 Week High | $17.88 | $44.28 |
| Indicator | SBGI | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 62.77 | 49.11 |
| Support Level | $12.93 | $33.90 |
| Resistance Level | $15.94 | $34.23 |
| Average True Range (ATR) | 0.74 | 2.03 |
| MACD | 0.25 | -0.15 |
| Stochastic Oscillator | 71.08 | 33.84 |
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets, covering 40% of US households. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their premium sports content to pay TV distributors.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.